Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ansa Biotechnologies has developed a proprietary enzymatic method for synthesizing long and complex custom DNA sequences. Their platform overcomes the length and complexity limitations of traditional chemical synthesis methods. The company now offers clonal synthetic genes up to at least 50 kb through an early access program. Their service has been validated by leading academic labs and industry partners for rapid delivery of highly accurate constructs that were previously considered too difficult or impossible to synthesize using legacy approaches.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ansa Biotechnologies.